Identifying HTA Outcomes and Assessing Reimbursement Implications for Drug X Through Evidence-based Considerations
The client’s objective was to understand HTA outcomes and reimbursement implications for a drug in Phase I for KRAS+ NSCLC patients in a particular region to support its SoC potential. The client faced significant challenges in determining whether Drug X, in Phase I for KRAS+ NSCLC patients, could be positioned as a standard of care (SoC) in third-line treatment. This was crucial for evidence generation, understanding reimbursement implications, and preparing a compelling value story for an upcoming Haute Autorité de Santé (HAS) meeting. The client needed clear guidance on SoC potential and the necessary evidence to secure favorable outcomes. Want to know how we supported our client in comprehending the HTA outcomes and reimbursement implications of the drug in Phase I for KRAS+ NSCLC patients, particularly in France? Fill out the form to access the full case study.Objective
Challenges faced by the client